on DBV TECHNOLOGIES (EPA:DBV)
DBV Technologies participation in the EAACI 2025 congress
DBV Technologies announces its participation in the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Congress in Glasgow. The event will take place from June 13th to 16th. The company will present two posters, host a symposium, and maintain an exhibition booth.
DBV presentations will focus on the results of the VIASKIN® Peanut Patch extension study and its effect in reducing peanut reactions in young children. In addition, the APTITUDE study on cow's milk allergy will also be discussed.
The "Peanut Allergy: Recent Research Highlights" symposium will be a highlight, featuring pediatric allergy experts such as Professors Gideon Lack and Alexandra Santos. These discussions aim to expand knowledge on epicutaneous immunotherapy for treating food allergies.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all DBV TECHNOLOGIES news